Ruping Ni

Ruping Ni

Auto-generated profile, based on publicly available information

Ruping Ni

Department of Clinical Pharmacy, Nanping First Hospital Affiliated to Fujian Medical University, Nanping, Fujian, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2023 in Hepatology Communications
Verified
Journal Article
Open access
CZcaiyun zheng
caiyun zheng
SHShunmin Huang
Shunmin Huang
MLMeimei Lin
Meimei Lin
BHBaohui Hong
Baohui Hong
RNRuping Ni
Ruping Ni
JYJing Yang
Jing Yang
Export Background: This systematic review and network meta-analysis aimed to provide a complete hepatotoxicity profile, hepatotoxicity spectrum, and safety ranking of immune checkpoint inhibitor drugs for cancer treatment. Methods: PubMed, Embase, Scopus, CINAHL, Web of Science, psycINFO, Cochrane Library, and ClinicalTrials.gov. websites were searched, and a manual search of relevant reviews and trials up to January 1, 2022, was undertaken. Head-to-head III randomized controlled trials comparing any 2 or 3 of the following treatments or different doses of the same immune checkpoint inhibitor drug were included: programmed death 1 (PD-1), programmed death ligand 1, and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) inhibitors and conventional therapy. We included 106 randomized trials (n=164,782) containing 17 treatment arms. Results: The overall incidence of hepatotoxicity was 4.06%. The rate of fatal liver adverse events was 0.07%. The programmed death ligand 1 inhibitor+targeted therapy drug+chemotherapy group had the highest risk of treatment-related increases in all-grade alanine aminotransferase and aspartate aminotransferase levels, and the differences were significant. For immune-related hepatotoxicity, no significant difference was found between PD-1 and CTLA-4 inhibitors for all-grade hepatotoxicity; however, CTLA-4 inhibitors were associated with a higher risk of grade 3–5 hepatotoxicity than PD-1 inhibitors. Conclusions: The highest incidence of hepatotoxicity and fatality was observed with triple therapy. The overall incidence of hepatotoxicity was similar between different dual regimens. For immune checkpoint inhibitor monotherapy, the overall risk of immune-mediated hepatotoxicity related to CTLA-4 inhibitors did not differ significantly from that of PD-1 inhibitors. There was no direct relationship between the risk of liver injury and drug dose, whether monotherapy or combination therapy was used.

16 August 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RNRuping Ni
Ruping Ni
MLMaobai Liu
Maobai Liu
SHShunmin Huang
Shunmin Huang
JYJing Yang
Jing Yang
Background: Patients undergoing heart surgery may experience a range of physiological changes, and the postoperative recovery time is long. Patients and their families often have concerns about quality of life (QoL) after discharge. eHealth interventions may improve patient participation, ensure positive and effective health management, improve the quality of at-home care and the patient's quality of life, and reduce rates of depression. Objective: The purpose of this study was to evaluate the effects of eHealth interventions on the physiology, psychology, and compliance of adult patients after cardiac surgery to provide a theoretical basis for clinical practice. Methods: We conducted systematic searches of the following 4 electronic databases: PubMed, Embase, CINAHL, and the Cochrane Central Register of Controlled Trials. Mean (SD) values were used to calculate the pooled effect sizes for all consecutive data, including QoL, anxiety, and depression. Where the same results were obtained using different instruments, we chose the standardized mean difference with a 95% CI to represent the combined effect size; otherwise, the mean difference (MD) with a 95% CI was used. Odds ratios were used to calculate the combined effect size for all dichotomous data. The Cohen Q test for chi-square distribution and an inconsistency index (I2) were used to test for heterogeneity among the studies. We chose a fixed-effects model to estimate the effect size if there was no significant heterogeneity in the data (I2≤50%); otherwise, a random-effects model was used. The quality of the included studies was assessed using the Cochrane risk-of-bias tool for randomized trials (RoB 2). Results: The search identified 3632 papers, of which 19 met the inclusion criteria. In terms of physical outcomes, the score of the control group was lower than that of the intervention group (MD 0.15, 95% CI 0.03-0.27, I2=0%, P=.02). There was no significant difference in the mental outcomes between the intervention and control groups (MD 0.10, 95% CI –0.03 to 0.24, I2=46.4%, P=.14). The control group’s score was lower than that of the intervention group for the depression outcomes (MD –0.53, 95% CI –0.89 to –0.17, I2=57.1%, P=.004). Compliance outcomes improved in most intervention groups. The results of the sensitivity analysis were robust. Nearly half of the included studies (9/19, 47%) had a moderate to high risk of bias. The quality of the evidence was medium to low. Conclusions: eHealth improved the physical component of quality of life and depression after cardiac surgery; however, there was no statistical difference in the mental component of quality of life. The effectiveness of eHealth on patient compliance has been debated. Further high-quality studies on digital health are required. Trial Registration: PROSPERO CRD42022327305; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=327305

10 August 2022 in Journal of Clinical Nursing
Verified
Journal Article
Closed access
MLMaobai Liu
Maobai Liu
RNRuping Ni
Ruping Ni
SHShunmin Huang
Shunmin Huang
XYXin Yang
Xin Yang
QLQinghua Lin
Qinghua Lin
JYJing Yang
Jing Yang

1 January 2026 in Pain Research and Management
Verified
Journal Article
Open access
PDF file
PHPing Huang
Ping Huang
TNTingting Nan
Tingting Nan
RNRuping Ni
Ruping Ni
YHYuhong Huang
Yuhong Huang
MLMaobai Liu
Maobai Liu
JYJing Yang
Jing Yang
Objectives: Treatments for neuropathic cancer pain (NCP) are often based on guidelines or treatment data for neuropathic pain of noncancer origin. Therefore, their relative efficacy and safety are not well characterized and should be determined. This study aimed to compare the efficacy and safety of various pharmacological interventions for NCP. Methods: We systematically searched PubMed/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for relevant randomized controlled trials (RCTs) from inception to June 13, 2024; 36 studies were included. The primary outcome was pain intensity; secondary outcomes included the effective pain relief rate, nausea and vomiting, and overall adverse events. The certainty of evidence was assessed using the CINeMA web application. Results: The combination of opioids, antiepileptics, and nonsteroidal anti‐inflammatory drugs (NSAIDs) appeared to be the most effective treatment to reduce pain intensity (surface under the cumulative ranking [SUCRA] curve: 0.91), followed by the combination of antiepileptics and antidepressants (SUCRA: 0.90). For secondary outcomes, the combination of opioids and neurotropin was associated with the highest probability of achieving the best pain relief rate (SUCRA: 0.81), whereas vitamin B12 appeared to be relatively ineffective. Regarding safety, vitamin B12 was associated with the highest probability of being the safest treatment for nausea and vomiting (SUCRA: 0.90), followed by antiepileptic drugs (SUCRA: 0.87). For overall adverse events, antidepressants were associated with the highest probability of being the safest treatment (SUCRA: 0.86). For the primary outcome, 84.8% of the comparisons were rated as being of low or very low confidence according to the CINeMA method. Conclusions: Antiepileptics and antidepressants, alone or in combination, and certain opioid‐based combinations may be effective for NCP based on current evidence, although the certainty of this evidence is low. Some plant‐derived compounds also demonstrated potential analgesic effects, although these findings are exploratory and based on a limited number of trials, and further evidence is needed to verify their efficacy. Given the low certainty of most comparisons, clinicians should interpret these results cautiously and balance potential benefits with safety profiles when selecting treatments for NCP.

7 April 2026 in BMJ Open
Verified
Journal Article
Open access
RNRuping Ni
Ruping Ni
ZGZhaowen Gao
Zhaowen Gao
ZJZhenghua Jiang
Zhenghua Jiang
XHXiaorui Hao
Xiaorui Hao
MZMingyuan Zhang
Mingyuan Zhang
PHPing Huang
Ping Huang
Introduction: Chronic postsurgical pain (CPSP) after hip arthroplasty is a major complication that affects patients’ long-term quality of life. However, reliable tools for the individualised prediction of CPSP risk after hip arthroplasty are lacking. This study aims to develop and validate a nomogram model to predict CPSP risk in patients undergoing hip arthroplasty. Methods and analysis: This prospective observational cohort study will consecutively recruit 300 patients undergoing primary hip arthroplasty at the Department of Orthopaedics and Joints, Nanping First Hospital Affiliated with Fujian Medical University. The primary outcome is CPSP assessed at 3 months postoperatively (Visual Analogue Scale score ≥4). Candidate predictor variables have been identified based on literature review and clinical expertise, and include demographics, comorbidities, preoperative pain, psychological status and surgical and perioperative management. The dataset will be randomly split into development and internal validation sets in a 7:3 ratio. We will employ Least Absolute Shrinkage and Selection Operator regression to select variables and will use multivariable logistic regression to build the final prediction model. Internal validation will be performed using bootstrap resampling (1000 repetitions). The model’s discrimination, calibration and clinical utility will be assessed using the C-statistic (area under the curve), calibration plots and decision curve analysis, respectively. The final model will be presented as a nomogram. Ethics and dissemination: The study protocol has been approved by the Ethics Committee of Nanping First Hospital (Approval No: NPSY202412034). All participants will provide written informed consent. The results will be submitted for publication in a peer-reviewed academic journal. Trial registration number: ChiCTR2500107193; https://www.chictr.org.cn/showproj.html?proj=282634 .